Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Total Non-Current Liabilities (2019 - 2026)

Alx Oncology Holdings' Total Non-Current Liabilities history spans 5 years, with the latest figure at $45.6 million for Q4 2023.

  • On a quarterly basis, Total Non-Current Liabilities rose 21.02% to $45.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $45.6 million, a 21.02% increase, with the full-year FY2023 number at $45.6 million, up 21.02% from a year prior.
  • Total Non-Current Liabilities hit $45.6 million in Q4 2023 for Alx Oncology Holdings, up from $44.7 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for ALXO hit a ceiling of $45.6 million in Q4 2023 and a floor of $6.2 million in Q4 2020.
  • Historically, Total Non-Current Liabilities has averaged $21.6 million across 5 years, with a median of $15.3 million in 2021.
  • Biggest five-year swings in Total Non-Current Liabilities: tumbled 40.37% in 2020 and later skyrocketed 146.58% in 2022.
  • Tracing ALXO's Total Non-Current Liabilities over 5 years: stood at $10.4 million in 2019, then tumbled by 40.37% to $6.2 million in 2020, then surged by 146.53% to $15.3 million in 2021, then skyrocketed by 146.58% to $37.7 million in 2022, then grew by 21.02% to $45.6 million in 2023.
  • Business Quant data shows Total Non-Current Liabilities for ALXO at $45.6 million in Q4 2023, $44.7 million in Q3 2023, and $27.1 million in Q2 2023.